Tg Therapeutics (TGTX) Other financing activities (2013 - 2026)

Tg Therapeutics' Other financing activities history runs 13 years deep, the most recent figure standing at $763000.0 for Q1 2026.

• On a quarterly basis, Other financing activities rose 3533.33% year-over-year to $763000.0 in Q1 2026; TTM through Mar 2026 was $2.3 million, a 150.33% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 69.97% from the prior year.
• Other financing activities retreated to $763000.0 in Q1 2026 per TGTX's latest filing, from $1.5 million in the prior quarter.
• Across five years, Other financing activities topped out at $1.5 million in Q4 2025 and bottomed at -$453000.0 in Q3 2025.
• The 5-year median for Other financing activities is $281000.0 (2023), against an average of $330062.5.
• Across the five-year window, Other financing activities sank 620.0% in 2022 and soared 3533.33% in 2026, its largest moves.
• Year by year, Other financing activities stood at $584000.0 in 2022, then fell by 28.08% to $420000.0 in 2023, then increased by 29.76% to $545000.0 in 2024, then soared by 177.25% to $1.5 million in 2025, then plunged by 49.5% to $763000.0 in 2026.
• Per Business Quant, the three latest TGTX Other financing activities figures stand at $763000.0 (Q1 2026), $1.5 million (Q4 2025), and -$453000.0 (Q3 2025).